Jan 3 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH + LOMB ANNOUNCES HEALTH CANADA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024%) FOR THE TREATMENT OF GLAUCOMA
* BAUSCH HEALTH COMPANIES - ON DECEMBER 27, 2018, HEALTH CANADA ISSUED NOTICE OF COMPLIANCE FOR VYZULTA